Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.
2.

Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.

Fujiwara M, Kwok S, Yano H, Pai RK.

Cancer Cytopathol. 2012 Aug 25;120(4):230-7. doi: 10.1002/cncy.21190. Epub 2012 Mar 20.

3.

Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology.

McKnight R, Nassar A, Cohen C, Siddiqui MT.

Cancer Cytopathol. 2012 Aug 25;120(4):223-9. doi: 10.1002/cncy.21184. Epub 2012 Feb 1.

6.
7.

Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma.

Krings G, Ramachandran R, Jain D, Wu TT, Yeh MM, Torbenson M, Kakar S.

Mod Pathol. 2013 Jun;26(6):782-91. doi: 10.1038/modpathol.2012.243. Epub 2013 Jan 25.

8.

Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.

Ibrahim TR, Abdel-Raouf SM.

Pathol Oncol Res. 2015 Apr;21(2):379-87. doi: 10.1007/s12253-014-9830-6. Epub 2014 Aug 10.

PMID:
25108409
9.

Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel.

Saleh HA, Aulicino M, Zaidi SY, Khan AZ, Masood S.

Diagn Cytopathol. 2009 Mar;37(3):184-90. doi: 10.1002/dc.20982.

PMID:
19170172
10.

Arginase-1: a highly specific marker separating pancreatic adenocarcinoma from hepatocellular carcinoma.

Fatima N, Cohen C, Siddiqui MT.

Acta Cytol. 2014;58(1):83-8. doi: 10.1159/000355629. Epub 2013 Nov 20.

PMID:
24281232
11.

Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.

Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, Evans M.

Cancer. 2007 Oct 25;111(5):316-22.

12.
13.

Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.

Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM, Chu PG.

Am J Surg Pathol. 2008 Mar;32(3):433-44. doi: 10.1097/PAS.0b013e318158142f.

PMID:
18300806
15.
16.

Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.

Ahuja A, Gupta N, Kalra N, Srinivasan R, Chawla Y, Rajwanshi A.

Cytopathology. 2008 Aug;19(4):229-35. Epub 2007 Dec 7.

PMID:
18070122
17.

Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology.

Saad RS, Luckasevic TM, Noga CM, Johnson DR, Silverman JF, Liu YL.

Diagn Cytopathol. 2004 Jan;30(1):1-6.

PMID:
14696137
18.

Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.

Zhang L, Liu H, Sun L, Li N, Ding H, Zheng J.

Acta Histochem. 2012 Oct;114(6):547-52. doi: 10.1016/j.acthis.2011.10.003. Epub 2011 Nov 26.

PMID:
22119409
19.

Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study.

Ligato S, Mandich D, Cartun RW.

Mod Pathol. 2008 May;21(5):626-31. doi: 10.1038/modpathol.2008.26. Epub 2008 Feb 8.

20.

Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.

Anatelli F, Chuang ST, Yang XJ, Wang HL.

Am J Clin Pathol. 2008 Aug;130(2):219-23. doi: 10.1309/WMB5PX57Y4P8QCTY.

PMID:
18628090

Supplemental Content

Support Center